Eisai Oncology Medical’s Post

Recent advances in medicine have led to declining cancer mortality rates. According to the American Cancer Society, overall cancer mortality has decreased by 33% since 1991. At Teva api, we are proud to contribute to this positive trend with our portfolio of oncology-related APIs. On this #WorldCancerDay, we stand resolute in our commitment to supporting a wide range of cancer treatments through our extensive portfolio of oncology-related APIs, including treatments for leukemia, breast cancer, lung cancer, prostate cancer, renal cell carcinoma, multiple myeloma, and ovarian cancer, thyroid cancer, gastrointestinal stromal tumors, and liver cancer. Let's unite in our mission to inspire hope and healing for those affected by cancer. Together, we can transform lives and shape a brighter future. https://lnkd.in/dw6PkyW2

Anti-TROP-2 antibody-drug conjugate sacituzumab tirumotecan (SKB264, also known as MK-2870) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation of the National Medical Products Administration of China for first-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative triple negative breast cancer. SKB264 is being developed as a further optimized TROP2-targeting ADC with a proprietary cytotoxic, belotecan-derived payload and novel stable conjugation chemistry to achieve average DAR of 7.4.  A marketing application for SKB264 for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer who have received at least 2 previous systemic treatments is undergoing priority review by the NMPA. #mabs https://lnkd.in/e88csvtB

Breast Cancer Key abstracts | ASCO 2024 As ASCO 2024 is approaching, major pharmaceutical firms such as AstraZeneca, Daiichi Sankyo US, Merck, Gilead Sciences, Eisai Co., Ltd., Pfizer, and more are poised to reveal the highly anticipated findings. Anticipated updates include safety and antitumor activity findings of BB-1701 in locally advanced/metastatic HER2-low expressing breast cancer, the initial outcomes of PF-07220060's Phase I/IIa study in patients with HR /HER2− metastatic breast cancer, survival data from DESTINY-Breast03 in patients with HER2 metastatic breast cancer, and further analyses of Phase III trial INAVO120 in patients with PIK3CA-mutated, HR /HER2‑negative locally advanced/metastatic breast cancer. For more detailed insights, visit: https://lnkd.in/gezZPj3Q #ASCO2024 #PharmaUpdates #BreastCancerResearch #BB1701 #PF07220060 #DESTINYBreast03 #INAVO120 #HER2Positive #HRPositive #MetastaticCancer #ClinicalTrials #MedicalResearch #CancerSurvival #TreatmentOutcomes #DataAnalysis

  Propanc Biopharma, Inc. (OTCQB:PPCB) Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent Office   Propanc Biopharma, Inc. (OTCQB:PPCB), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s "composition of proenzymes for cancer treatment," patent was received from the European Patent Office. The patent covers lower dosage ratios of the two proenzymes (trypsinogen and chymotrypsinogen) contained in the PRP formulation. This is the fourth European patent granted and after validation in selected countries across Europe, will result in the Company’s IP portfolio growing to 94 patents filed in major global jurisdictions.   https://lnkd.in/gjvFQEzx   #propanc #ppcb #biopharma #cancer #oncology James Nathanielsz  

The publication of our manuscript, "Efficacy and Safety of Treatments Used in Differentiated Thyroid Cancer (DTC): A Systematic Review " Patients diagnosed with differentiated thyroid cancer (DTC) are offered multiple targeted therapeutics, but it is unclear which pharmaceutical therapies are most effective and safe. A systematic literature review (SLR) was performed to assess the clinical efficacy and safety of targeted therapeutics in DTC patients. A comprehensive search was performed across MEDLINE®, Embase®, and Evidence-based Medicine (EBM) Reviews databases, along with a grey literature search. Read the full analysis and insights here: 👉 https://lnkd.in/dt_4USRh 👈 Reminder: Formerly SRS HEOR is now Amethys Insights #thyroidcancer #differentiatedthyroidcancer #cancerresearch #targetedtherapies #cancertreatment #medicalresearch #pharma #systematicreview #clinicaltrials #cancercare #healthcare

Raptim Research Celebrates a Breakthrough in Cancer Treatment! We're thrilled to announce that a novel treatment for Renal Cell Carcinoma (RCC) and other cancers has received USFDA approval! This achievement signifies a significant leap forward in cancer care, offering new hope for patients battling these challenging diseases. Our team at Raptim Research is proud to have played a key role in this groundbreaking initiative. Through a patient-based PK/BE study, we provided crucial data on the treatment's safety, efficacy, and quality, ultimately supporting its path to regulatory approval. This collaboration highlights the power of research and collaboration in advancing cancer care. We're honored to have partnered with industry leaders on this transformative project. Join us in celebrating this milestone and the potential impact it holds for cancer patients! Want to learn more about our expertise in PK/BE studies and how we can support your clinical research needs? Visit our website: https://lnkd.in/dadHP4qk Contact us directly to discuss collaboration opportunities. Together, let's continue making meaningful contributions to the fight against cancer. #cancerresearch #clinicalresearch #breakthrough #FDAapproval #RaptimResearch

Propanc Biopharma, Inc. (OTCQB:PPCB) Receives Certificate of Grant for "Composition of Proenzymes for Cancer Treatment" Patent from European Patent Office   Propanc Biopharma, Inc. (OTCQB:PPCB), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s "composition of proenzymes for cancer treatment," patent was received from the European Patent Office. The patent covers lower dosage ratios of the two proenzymes (trypsinogen and chymotrypsinogen) contained in the PRP formulation. This is the fourth European patent granted and after validation in selected countries across Europe, will result in the Company’s IP portfolio growing to 94 patents filed in major global jurisdictions.   https://lnkd.in/gjvFQEzx   #propanc #ppcb #biopharma #cancer #oncology James Nathanielsz  

“After 33 years, Geron finally crosses FDA finish line with blood cancer med Rytelo” California based Bio-Tech firm, Geron, have made headlines in recent weeks having secured their long-awaited FDA approval of Rytelo, a blood cancer drug designed to treat a series of rare bone marrow disorders called myelodysplastic syndromes (MDS). But just how long-awaited are we talking? Try an eye-watering 33 years… This is the first time the company have had rubber hit road in three decades, with Rytelo representing just another iteration of a long list of Geron drug candidates put to task against the incredibly stringent drug approval process of the FDA. Geron CEO John Scarlett had this to say on the news: “With the approval and availability of Rytelo, we believe eligible patients with lower-risk MDS can potentially experience meaningful clinical benefit, particularly the potential for greater than 24 weeks of freedom from the burden of red blood cell transfusions and symptomatic anaemia,”. For more bi-weekly updates on the biggest happenings in the pharmaceutical industry, sign up to our newsletter in the link below! 🔬 #lifesciences #pharmaceuticals #biotechnology #underthemicroscope #oncology #cancertreatment #FDA 

Very grateful to CDDF and ESMO for inviting me to participate in this session. Looking forward to sharing some regulatory input with Oncolleagues at ESMO 2024! I will essentially try to convey what I wish I knew about medicinal product regulation while I still was a practicing Oncologist, here's a sneak peek of the questions I will try to respond: •How are new medicinal products approved in Europe? What is the CHMP? •Who are the Rapporteur and the Co-Rapporteur for a product? What is their role? •What is the centralised procedure? •What types of approval (i.e., marketing authorisation) are there? •What do clinical assessors in the regulatory network base their assessments upon? •What is an EPAR? What is an SmPC? Where do I find them? I will provide Oncology-specific examples, while presenting my personal summary on EMA’s anticancer guideline V6 and CHMP's policy.

FDA approved amivantamab-vmjw (Rybrevant, The Janssen Pharmaceutical Companies of Johnson & Johnson) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor https://lnkd.in/g65bDCcM